STUDY ON PRESCRIPTION PATTERN OF ANTI-DIABETIC MEDICATION AMONG TYPE 2 DIABETES MELLITUS PATIENTS
AbstractBackground: Diabetes mellitus (T2DM) is a disorder in which the amount of sugar in the blood is elevated. Doctors often use the full name that is Diabetes Mellitus rather than Diabetes alone to differentiate from Diabetes Insipidus. Diabetes Insipidus is a relatively rare disorder that does not affect the blood glucose levels but just like Diabetes Mellitus, causing increased urination. Method: A prospective observational study was carried out among T2DM patients. Patient demographics, medication details, and blood glucose levels were recorded, examined, and the prescription pattern of the doctors was analyzed. Result and Discussion: The study included 209 T2DM patients. Metformin was more frequently prescribed single drug in 7.60% of participants. Dual drug combinations were Metformin and Glimepiride (49.04%), Metformin and Dapagliflozin (4.56%), Metformin and Vildagliptin (6.84%). About 61.84% were prescribed with short-acting insulin, 26.31% with intermediate-acting insulin, 10.52% with long-acting insulin, and only 1.31% of participants were prescribed with rapid-acting insulin. Dual drug fixed dose combination, Metformin is commonly combined with Glimepiride. A unique combination encountered was Remogliflozin and Vildagliptin. In the triple drug fixed dose combination, Metformin and Glimepiride were combined either with Voglibose or Pioglitazone. Regular insulin is more commonly used as add-on therapy (48.21%). Insulin Glargine, Insulin Aspart, and Insulin with NPH were used. Conclusion: This study provides a novel insight into the prescribing pattern taken up by physicians to strategize the drug regimen and improve the health of the population.
Article Information
38
2500-2506
554 KB
38
English
IJPSR
Melvin Kurian Abraham *, S. Kavya, C. Y. Rameshwar and Mohammed Mustafa Gadwal
Malayil Choorackal, East Othera P. O, Eraviperoor, Pathanamthitta, Kerala, India.
melvinkurian98@gmail.com
10 March 2024
13 April 2024
24 April 2024
10.13040/IJPSR.0975-8232.15(8).2500-06
01 August 2024